CA2382556A1 - Coformulation methods and their products - Google Patents
Coformulation methods and their products Download PDFInfo
- Publication number
- CA2382556A1 CA2382556A1 CA002382556A CA2382556A CA2382556A1 CA 2382556 A1 CA2382556 A1 CA 2382556A1 CA 002382556 A CA002382556 A CA 002382556A CA 2382556 A CA2382556 A CA 2382556A CA 2382556 A1 CA2382556 A1 CA 2382556A1
- Authority
- CA
- Canada
- Prior art keywords
- coformulation
- active substance
- oligomeric
- amorphous
- polymeric material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/04—Solvent extraction of solutions which are liquid
- B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/04—Solvent extraction of solutions which are liquid
- B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
- B01D11/0407—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solute
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/04—Solvent extraction of solutions which are liquid
- B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
- B01D11/0411—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/04—Solvent extraction of solutions which are liquid
- B01D11/0488—Flow sheets
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9920558.5 | 1999-08-31 | ||
GBGB9920558.5A GB9920558D0 (en) | 1999-08-31 | 1999-08-31 | Methods for particle formation and their products |
PCT/GB2000/003328 WO2001015664A2 (en) | 1999-08-31 | 2000-08-31 | Coformulation methods and their products |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2382556A1 true CA2382556A1 (en) | 2001-03-08 |
Family
ID=10860085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002382556A Abandoned CA2382556A1 (en) | 1999-08-31 | 2000-08-31 | Coformulation methods and their products |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1207856A2 (ko) |
JP (1) | JP2003508419A (ko) |
KR (1) | KR20020047137A (ko) |
AU (1) | AU783570B2 (ko) |
CA (1) | CA2382556A1 (ko) |
GB (2) | GB9920558D0 (ko) |
MX (1) | MXPA02001803A (ko) |
WO (1) | WO2001015664A2 (ko) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0201450A3 (en) | 1999-12-08 | 2003-02-28 | Pharmacia Corp Chicago | Solid-state form of celecoxib having enhanced bioavailability, pharmaceutical compositions containing it and their preparation |
CH694686A5 (it) | 2000-03-04 | 2005-06-15 | Eco2 Sa | Prodotto di micronizzazione di sostanze farmaceutiche. |
FR2815540B1 (fr) † | 2000-10-19 | 2005-06-10 | Separex Sa | Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote |
GB0027357D0 (en) | 2000-11-09 | 2000-12-27 | Bradford Particle Design Plc | Particle formation methods and their products |
GB0102075D0 (en) | 2001-01-26 | 2001-03-14 | Astrazeneca Ab | Process |
DK1401404T3 (da) * | 2001-05-30 | 2008-08-11 | Csir | Fremgangsmåde til indkapsling af et aktivt stof |
US20050271737A1 (en) * | 2001-06-07 | 2005-12-08 | Chinea Vanessa I | Application of a bioactive agent to a substrate |
US7767249B2 (en) * | 2001-06-07 | 2010-08-03 | Hewlett-Packard Development Company, L.P. | Preparation of nanoparticles |
US20050260273A1 (en) * | 2001-06-07 | 2005-11-24 | Chinea Vanessa I | Applicatin of a bioactive agent in a solvent composition to produce a target particle morphology |
EP1404300B1 (en) | 2001-06-22 | 2009-09-30 | Pfizer Products Inc. | Pharmaceutical compositions of dispersions of drugs and neutral polymers |
GB0208742D0 (en) | 2002-04-17 | 2002-05-29 | Bradford Particle Design Ltd | Particulate materials |
EP1440082B1 (en) | 2001-10-22 | 2011-09-28 | Dompé S.P.A. | Supercritical fluids processing: preparation of protein microparticles and their stabilisation |
EP1446104B2 (en) | 2001-11-01 | 2011-08-03 | Novartis AG | Spray drying methods |
ATE395044T1 (de) | 2002-02-01 | 2008-05-15 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien |
US9339459B2 (en) | 2003-04-24 | 2016-05-17 | Nektar Therapeutics | Particulate materials |
CA2524773C (en) | 2003-05-08 | 2014-04-08 | Nektar Therapeutics Uk Ltd | Particulate coformulations of active substances with excipients |
JP2007501218A (ja) | 2003-08-04 | 2007-01-25 | ファイザー・プロダクツ・インク | 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物 |
US7507823B2 (en) | 2004-05-06 | 2009-03-24 | Bristol-Myers Squibb Company | Process of making aripiprazole particles |
ES2472699T3 (es) | 2006-10-11 | 2014-07-02 | Crititech, Inc. | Aparato para precipitación de partículas pequeñas de medicamento en recipientes de uso |
GB0702402D0 (en) * | 2007-02-08 | 2007-03-21 | Thar Pharmaceuticals Inc | Method of creating crystalline substances |
PL2425820T3 (pl) | 2007-02-11 | 2015-08-31 | Map Pharmaceuticals Inc | Sposób terapeutycznego stosowania dhe w celu umożliwienia szybkiego złagodzenia migreny przy jednoczesnym zminimalizowaniu profilu działań niepożądanych |
US8585943B2 (en) | 2007-12-07 | 2013-11-19 | Xspray Microparticles Ab | Method and arrangement for the production of particles |
GB0812742D0 (en) | 2008-07-11 | 2008-08-20 | Critical Pharmaceuticals Ltd | Process |
US9808030B2 (en) | 2011-02-11 | 2017-11-07 | Grain Processing Corporation | Salt composition |
ES2854751T3 (es) * | 2012-01-13 | 2021-09-22 | Xspray Microparticles Ab | Un procedimiento para producir nanopartículas híbridas amorfas estables que comprende al menos un inhibidor de la proteína cinasa y al menos un componente polimérico estabilizante y formador de matriz |
WO2013105894A1 (en) * | 2012-01-13 | 2013-07-18 | Xspray Microparticles Ab | A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component. |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1146866A (en) * | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
EP0462066A1 (en) * | 1990-06-15 | 1991-12-18 | Warner-Lambert Company | Amorphous gemfibrozil |
DE4041563A1 (de) * | 1990-12-22 | 1992-06-25 | Sanol Arznei Schwarz Gmbh | Verfahren zur herstellung wirkstoffhaltiger mikropartikel aus hydrolytisch abbaubaren polymeren |
IT1255792B (it) * | 1992-08-05 | 1995-11-16 | Bayer Italia Spa | Composizioni farmaceutiche per la somministrazione orale di diidropiridine in forma di bevanda |
GB9313642D0 (en) * | 1993-07-01 | 1993-08-18 | Glaxo Group Ltd | Method and apparatus for the formation of particles |
US5773025A (en) * | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
IE75744B1 (en) * | 1995-04-03 | 1997-09-24 | Elan Corp Plc | Controlled release biodegradable micro- and nanospheres containing cyclosporin |
SI9500173B (sl) * | 1995-05-19 | 2002-02-28 | Lek, | Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo |
TW487582B (en) * | 1995-08-11 | 2002-05-21 | Nissan Chemical Ind Ltd | Method for converting sparingly water-soluble medical substance to amorphous state |
AU709384B2 (en) * | 1996-03-01 | 1999-08-26 | University Of Kansas, The | Methods and apparatus for particle precipitation and coating using near-critical and supercritical antisolvents |
BR9709097A (pt) * | 1996-05-17 | 1999-08-03 | Merck & Co Inc | Composição farmacêutica para o tratamento de doenças mediadas por ciclooxigenase processo para tratar uma doença inflamatória suscetível de tratamento com um agente antinflamatório n o esteróide uso e forma oral de dose unitária |
FR2753639B1 (fr) * | 1996-09-25 | 1998-12-11 | Procede de preparation de microcapsules de matieres actives enrobees par un polymere et nouvelles microcapsules notamment obtenues selon le procede | |
US5980942A (en) * | 1997-01-23 | 1999-11-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Zero-order sustained release matrix tablet formulations of carbamazepine |
IT1296464B1 (it) * | 1997-11-19 | 1999-06-25 | Vectorpharma Int | Composizioni farmaceutiche in forma di polveri di polimeri reticolati caricati con farmaci e relativo processo di preparazione mediante |
DE19821951A1 (de) * | 1998-05-15 | 1999-11-18 | Basf Ag | Cyclosporin-Zubereitungen |
US6465011B2 (en) * | 1999-05-29 | 2002-10-15 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
GB9915975D0 (en) * | 1999-07-07 | 1999-09-08 | Bradford Particle Design Ltd | Method for the formation of particles |
-
1999
- 1999-08-31 GB GBGB9920558.5A patent/GB9920558D0/en not_active Ceased
-
2000
- 2000-08-31 EP EP00956682A patent/EP1207856A2/en not_active Withdrawn
- 2000-08-31 GB GB0021227A patent/GB2355194B/en not_active Expired - Fee Related
- 2000-08-31 CA CA002382556A patent/CA2382556A1/en not_active Abandoned
- 2000-08-31 KR KR1020027002715A patent/KR20020047137A/ko not_active Application Discontinuation
- 2000-08-31 JP JP2001519878A patent/JP2003508419A/ja active Pending
- 2000-08-31 WO PCT/GB2000/003328 patent/WO2001015664A2/en not_active Application Discontinuation
- 2000-08-31 MX MXPA02001803A patent/MXPA02001803A/es active IP Right Grant
- 2000-08-31 AU AU68550/00A patent/AU783570B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
WO2001015664A3 (en) | 2001-09-20 |
EP1207856A2 (en) | 2002-05-29 |
GB0021227D0 (en) | 2000-10-18 |
AU783570B2 (en) | 2005-11-10 |
KR20020047137A (ko) | 2002-06-21 |
GB2355194A (en) | 2001-04-18 |
AU6855000A (en) | 2001-03-26 |
WO2001015664A2 (en) | 2001-03-08 |
MXPA02001803A (es) | 2004-02-26 |
GB2355194B (en) | 2003-01-08 |
JP2003508419A (ja) | 2003-03-04 |
GB9920558D0 (en) | 1999-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2382556A1 (en) | Coformulation methods and their products | |
Majerik et al. | Bioavailability enhancement of an active substance by supercritical antisolvent precipitation | |
Yan et al. | Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes | |
Vimalson | Techniques to enhance solubility of hydrophobic drugs: an overview | |
Vasconcelos et al. | Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs | |
Savjani et al. | Drug solubility: importance and enhancement techniques | |
Taki et al. | Controlled release system formed by supercritical anti-solvent coprecipitation of a herbicide and a biodegradable polymer | |
Yasuji et al. | Particle design of poorly water-soluble drug substances using supercritical fluid technologies | |
Muhrer et al. | Use of compressed gas precipitation to enhance the dissolution behavior of a poorly water-soluble drug: generation of drug microparticles and drug–polymer solid dispersions | |
Tandya et al. | Micronization of cyclosporine using dense gas techniques | |
Jatwani et al. | An overview on solubility enhancement techniques for poorly soluble drugs and solid dispersion as an eminent strategic approach | |
Lee et al. | Bioavailability of cyclosporin A dispersed in sodium lauryl sulfate–dextrin based solid microspheres | |
WO1997004749A1 (fr) | Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees | |
Kim et al. | Development of a novel l-sulpiride-loaded quaternary microcapsule: Effect of TPGS as an absorption enhancer on physicochemical characterization and oral bioavailability | |
EP2170289A2 (en) | Preparation method for solid disupersions | |
Badens et al. | Comparison of solid dispersions produced by supercritical antisolvent and spray-freezing technologies | |
Ogienko et al. | Cryosynthesis of Co-Crystals of Poorly Water-Soluble Pharmaceutical Compounds and Their Solid Dispersions with Polymers. The “Meloxicam–Succinic Acid” System as a Case Study | |
US20060160871A1 (en) | Stable non-crystalline formulation comprising losartan | |
WO2010102245A1 (en) | Solid dispersion comprising resveratrol | |
Shi et al. | The influence of cellulosic polymer’s variables on dissolution/solubility of amorphous felodipine and crystallization inhibition from a supersaturated state | |
Vig et al. | Formulation, process development, and scale-up: Spray-drying amorphous solid dispersions for insoluble drugs | |
Yousaf et al. | Novel fenofibrate-loaded gelatin microcapsules with enhanced solubility and excellent flowability: preparation and physicochemical characterization | |
Roy et al. | Theophylline formulation by supercritical antisolvents | |
Mezzomo et al. | Nanosizing of sodium ibuprofen by SAS method | |
WO2006074066A1 (en) | Non-crystalline formulation comprising clopidogrel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |